Total Payments
$1.7M
2024 Payments
$90,781
Companies
22
Transactions
1,053
Payment Breakdown by Category
Other$951,062 (57.5%)
Research$451,750 (27.3%)
Consulting$143,686 (8.7%)
Travel$91,718 (5.5%)
Food & Beverage$14,562 (0.9%)
Education$264.90 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $912,562 | 364 | 55.2% |
| Unspecified | $451,750 | 63 | 27.3% |
| Consulting Fee | $143,686 | 50 | 8.7% |
| Travel and Lodging | $91,718 | 273 | 5.5% |
| Honoraria | $38,500 | 16 | 2.3% |
| Food and Beverage | $14,562 | 274 | 0.9% |
| Education | $264.90 | 13 | 0.0% |
Payments by Type
General
$1.2M
990 transactions
Research
$451,750
63 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $539,909 | 473 | $0 (2024) |
| ABBVIE INC. | $331,185 | 263 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $193,858 | 121 | $0 (2022) |
| Nielsen BioSciences, Inc. | $153,698 | 5 | $0 (2024) |
| Almirall LLC | $136,891 | 13 | $0 (2023) |
| Eli Lilly and Company | $130,901 | 29 | $0 (2024) |
| Janssen Biotech, Inc. | $53,632 | 67 | $0 (2024) |
| DERMIRA, INC. | $22,854 | 18 | $0 (2019) |
| Aqua Pharmaceuticals | $18,750 | 10 | $0 (2017) |
| Arcutis Biotherapeutics, Inc. | $16,790 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $90,781 | 53 | Lilly USA, LLC ($36,313) |
| 2023 | $237,119 | 135 | Lilly USA, LLC ($106,542) |
| 2022 | $304,712 | 177 | ABBVIE INC. ($100,380) |
| 2021 | $82,945 | 50 | AbbVie Inc. ($38,004) |
| 2020 | $137,003 | 72 | Lilly USA, LLC ($41,092) |
| 2019 | $338,238 | 204 | Lilly USA, LLC ($101,549) |
| 2018 | $233,058 | 182 | Lilly USA, LLC ($85,081) |
| 2017 | $229,186 | 180 | Lilly USA, LLC ($83,366) |
All Payment Transactions
1,053 individual payment records from CMS Open Payments — Page 1 of 43
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | PFIZER INC. | LITFULO (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: LITFULO CLINICAL PUBLICATION PROGRAM • Category: IMMUNOLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,625.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/02/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,625.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Immunology | ||||||
| 11/06/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $123.16 | General |
| Category: IMMUNOLOGY | ||||||
| 10/29/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Immunology | ||||||
| 10/24/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $125.01 | General |
| Category: IMMUNOLOGY | ||||||
| 10/17/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $400.00 | General |
| Category: Immunology | ||||||
| 10/16/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $25.39 | General |
| Category: Immunology | ||||||
| 09/22/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,050.00 | General |
| Category: Immunology | ||||||
| 09/20/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,625.00 | General |
| Category: IMMUNOLOGY | ||||||
| 09/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Immunology | ||||||
| 09/16/2024 | Eli Lilly and Company | TALTZ (Drug) | — | In-kind items and services | $104.58 | Research |
| Study: EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) • Category: Immunology | ||||||
| 08/28/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $124.93 | General |
| Category: IMMUNOLOGY | ||||||
| 08/16/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Immunology | ||||||
| 08/12/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: Immunology | ||||||
| 07/12/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| Category: Immunology | ||||||
| 07/01/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: Immunology | ||||||
| 06/27/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: Immunology | ||||||
| 06/13/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Immunology | ||||||
| 06/12/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,200.00 | General |
| Category: Immunology | ||||||
| 06/12/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: Immunology | ||||||
| 06/10/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,625.00 | General |
| Category: IMMUNOLOGY | ||||||
| 05/31/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,087.50 | General |
| Category: IMMUNOLOGY | ||||||
| 05/30/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,200.00 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| M14867-32 | Almirall LLC | $133,141 | 11 |
| CFW-2D | Nielsen BioSciences, Inc. | $125,098 | 3 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $47,653 | 4 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $29,399 | 3 |
| CFW-3A | Nielsen BioSciences, Inc. | $28,600 | 2 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | Eli Lilly and Company | $14,325 | 3 |
| A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $13,957 | 4 |
| A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH PSORIASIS | Eli Lilly and Company | $13,058 | 4 |
| A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH ATOPIC DERMATITIS | Eli Lilly and Company | $10,231 | 4 |
| A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis | Arcutis Biotherapeutics, Inc. | $10,084 | 3 |
| BREPOCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $9,200 | 4 |
| A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis | Arcutis Biotherapeutics, Inc. | $6,706 | 3 |
| LITFULO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| A STUDY OF GLYCOPYRRONIUM CLOTH, 2.4% IN PATIENTS WITH PALMAR HYPERHIDROSIS | DERMIRA, INC. | $3,193 | 5 |
| A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 | Eli Lilly and Company | $1,125 | 2 |
| INFLAMIMMUNO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $766.24 | 3 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE- AND PLACEBO-CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF OPC-64005 IN THE TREATMENT OF ADULT ATTENTION-DEFICITHYPERACTIVITY DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $687.50 | 1 |
| A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED WITHDRAWAL MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-1 | Eli Lilly and Company | $282.38 | 1 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | Eli Lilly and Company | $104.58 | 1 |
About Dr. Stacy Smith, M.D
Dr. Stacy Smith, M.D is a Dermatology healthcare provider based in Encinitas, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1780651760.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stacy Smith, M.D has received a total of $1.7M in payments from pharmaceutical and medical device companies, with $90,781 received in 2024. These payments were reported across 1,053 transactions from 22 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($912,562).
Ad
Practice Information
- Specialty Dermatology
- Location Encinitas, CA
- Active Since 03/08/2006
- Last Updated 10/29/2013
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1780651760
Products in Payments
- TALTZ (Drug) $356,876
- TREMFYA (Drug) $109,319
- Tremfya (Drug) $109,199
- RINVOQ (Biological) $108,724
- SKYRIZI (Biological) $107,050
- OLUMIANT (Drug) $103,340
- Candin (Biological) $75,095
- Humira (Biological) $47,166
- Skyrizi (Biological) $37,174
- Olumiant (Drug) $33,331
- QBREXZA (Drug) $19,661
- STELARA (Biological) $17,284
- COSENTYX (Biological) $11,755
- Zoryve (Drug) $10,084
- ILUMYA (tildrakizumab-asmn) injection (Biological) $7,068
- HUMIRA (Biological) $6,344
- LITFULO (Drug) $3,200
- OTHER $3,193
- SIMPONI ARIA (Biological) $3,130
- Cloderm Cream (Drug) $350.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Encinitas
Dr. Stacy Tompkins, Md, MD
Dermatology — Payments: $8,271
Dermatology $8,271
Lisa Stirling, M.d, M.D
Dermatology — Payments: $6,541
Dermatology $6,541
Dr. Margaret Dupree, Md, MD
Dermatology — Payments: $6,461
Dermatology $6,461
Dr. Andres Cruz-Inigo, M.d, M.D
Dermatology — Payments: $2,240
Dermatology $2,240
Elizabeth Cooper
Dermatology — Payments: $1,897
Dermatology $1,897
Kathleen O'brien
Dermatology — Payments: $880.08
Dermatology $880.08